Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
Alimentary Pharmacology & Therapeutics · 2025-12 · 62 (11-12) · 1089-1099
DOI: 10.1111/apt.70382 ↗At a glance
Klinische Studie (Phase III) in Alimentary Pharmacology & Therapeutics, published online on 2025-10-23. Written by Mazen Noureddin and 7 co-authors. Institution: Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Fatty Liver, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Cited 38 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Madrigal Pharmaceuticals.
Topics: Diabetes mellitus
Abstract (original language)
Background
MAESTRO‐NASH, a randomised, double‐blind, placebo‐controlled, 54‐month phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy‐confirmed metabolic‐dysfunction associated steatohepatitis (MASH) and liver fibrosis achieved primary endpoints of MASH resolution with no worsening of fibrosis, and ≥ 1‐stage improvement in fibrosis with no worsening of MASH at 52‐weeks.
Aims
The effects of resmetirom (80 or 100 mg) versus placebo were evaluated on Week 52 histological and biomarker endpoints in relation to background treatment with sodium‐glucose cotransporter 2 inhibitors (SGLT2i), GLP‐1 receptor agonists (GLP‐1 RA), and/or ≥ 5% weight loss at Week 52.
Methods
At baseline, 13%–17% of patients (all with type 2 diabetes mellitus [T2DM]) were on stable GLP‐1 RA or SGLT2i therapy. Changes in liver histology, MRI‐proton density fat fraction (MRI‐PDFF), and liver stiffness were examined after 52 weeks of treatment.
Results
No weight loss above baseline occurred with GLP‐1 RA or SGLT2i therapy. SGLT2 and GLP‐1 RA treated patients showed similar rates of MASH resolution and fibrosis improvement in combination with resmetirom as patients not on these therapies. Resmetirom‐treated patients (100 mg) with weight loss (≥ 5%) compared with those with weight loss < 5% had higher rates of MASH resolution (56.6% vs. 33.8%), fibrosis improvement (40.6% vs. 31.5%), MRI‐PDFF reduction (−69% vs. −46%), and liver stiffness reduction after 52 weeks of treatment (−4.6 kPa vs. −2.3 kPa).
Conclusions
The efficacy of resmetirom on multiple MASH endpoints was not impacted by background SGLT2i or GLP‐1 RA treatment. Weight loss (≥ 5%) enhanced the efficacy of resmetirom. Trial Registration MAESTRO‐NASH ClinicalTrials.gov number, NCT03900429
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Houston Methodist Hospital, Houston, Texas, USA.
- Houston Research Institute, Houston, Texas, USA.
- University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA.
- Madrigal Pharmaceuticals, West Conshohocken, Pennsylvania, USA.
- Summit Clinical Research, San Antonio, Texas, USA.
- MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
ORCID profiles: Naim Alkhouri, Rohit Loomba, Meena B Bansal
Funding
- Madrigal Pharmaceuticals
Cite
APA
Noureddin, M., Rinella, M., Taub, R., Labriola, D., Camacho, R. C., Alkhouri, N., Loomba, R., & Bansal, M. B. (2025). Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial. Alimentary Pharmacology & Therapeutics, 62(11-12), 1089-1099. https://doi.org/10.1111/apt.70382
Vancouver
Noureddin M, Rinella M, Taub R, Labriola D, Camacho RC, Alkhouri N, et al. Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial. Alimentary Pharmacology & Therapeutics. 2025;62(11-12):1089-1099. doi:10.1111/apt.70382
BibTeX
@article{Noureddin2025,
author = {Noureddin, Mazen and Rinella, Mary and Taub, Rebecca and Labriola, Dominic and Camacho, Raul C and Alkhouri, Naim and Loomba, Rohit and Bansal, Meena B},
title = {Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {62},
number = {11-12},
pages = {1089--1099},
doi = {10.1111/apt.70382}
}
EUVIMED